Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
92 hedge funds and large institutions have $68.7M invested in Bellicum Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 21 closing their positions.
12% more call options, than puts
Call options by funds: $38K | Put options by funds: $34K
8% less funds holding
Funds holding: 100 → 92 (-8)
21% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 29
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
54% less capital invested
Capital invested by funds: $150M → $68.7M (-$81.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.01M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.97M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$810K |
| 4 |
Two Sigma Investments
New York
|
+$762K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.04M |
| 2 |
BlackRock
New York
|
-$2.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.87M |
| 4 |
Millennium Management
New York
|
-$1.02M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.02M |
BLCM Hedge Fund Activity: Q4 2018 in Review
92 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2018, worth a combined $68.7M — down 54% from $150M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BLCM and 14 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 23 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.01M. The largest seller was Farallon Capital Management, cutting an estimated $5.04M.
- 92 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2018, down from 100 in Q3 2018.
- Funds reported $68.7M of Bellicum Pharmaceuticals, Inc. stock for Q4 2018, down 54% quarter-over-quarter.
- 14 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2018 and 21 closed out, a net change of -7 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2018 was Renaissance Technologies, an estimated $2.01M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2018 was Farallon Capital Management, an estimated $5.04M sold.
Based on aggregated 13F filings for Q4 2018.